Advertisement

Chemopreventive Efficacy of Natural Vitamin D and Synthetic Analogs

  • Kathryn Z. Guyton
  • Thomas W. Kensler
  • Gary H. Posner
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The activities of vitamin D and synthetic vitamin D analogs (deltanoids) are primarily mediated through binding to vitamin D receptors (VDRs), members of the steroid/thyroid receptor superfamily. Chemopreventive properties of this class of compounds include in vitro and in vivo antiproliferative, pro-apoptotic, pro-differentiating, and anti-angiogenic activities. Natural vitamin D and a number of deltanoids have shown chemopreventive efficacy in preclinical studies. Although also supported by substantial epidemiologic data, the development of natural vitamin D as a cancer chemopreventive has been hindered by dose-limiting hypercalcemic effects. Unfortunately, these same safety concerns also apply to many deltanoids, including those approved for treatment of secondary hyperparathyroidism in patients with end-stage renal disease. However, several new synthetic deltanoids have recently shown promise in preclinical safety and chemopreventive efficacy studies.

Keywords

Prostate Cancer Colorectal Adenoma Prostate Cancer Risk Hybrid Analog Natural Vitamin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1α-hydroxylase. J Clin Endocrinol Metab 2001;86:888–894.PubMedGoogle Scholar
  2. 2.
    Segaert S, Bouillon R. Vitamin D and regulation of gene expression. Curr Opin Clin Nutr Metab Care 1998;1:347–354.PubMedGoogle Scholar
  3. 3.
    Verlinden L, Verstuyf A, Van Camp M, et al. Two novel 14-epianalogues of 1,25-Dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 2000;60:2673–2679.PubMedGoogle Scholar
  4. 4.
    Jaaskelainen T, Ryhanen S, Mahonen A, et al. Mechanism of action of superactive vitamin D analogs through regulated receptor degradation. J Cell Biochem 2000;76:548–558.PubMedGoogle Scholar
  5. 5.
    Minghetti PP, Norman AW. 1,25(OH)2-vitamin D3 receptors: gene regulation and genetic circuitry. FASEB J 1988;2:3043–3053.PubMedGoogle Scholar
  6. 6.
    Norman AW, Bishop JE, Bula CM, et al. Molecular tools for study of the genomic and rapid signal transduction respons-es initiated by 1-α,25-dihidroxyvitamin D3. Steroids 2002;67:457–466.PubMedGoogle Scholar
  7. 7.
    Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200–257.PubMedGoogle Scholar
  8. 8.
    Mathiasen IS, Colston KW, Binderup L. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differ-entiation inducing effects on cancer cells. J Steroid Biochem Mol Biol 1993;46:365–371.PubMedGoogle Scholar
  9. 9.
    Grue-Sorensen G, Hansen CM. New 1α,25-dihydroxy vitamin D3 analogues with side chains attached to C-18: synthesis and biological activity. Bioorg Med Chem 1998;6:2029–2039.PubMedGoogle Scholar
  10. 10.
    Uskokovic MR, Studzinski GP, Gardner JP, et al. The 16-ene vitamin D analogues. Curr Pharm Des 1997;3:99–123.Google Scholar
  11. 11.
    Abe J, Nakano T, Nishii Y, et al. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991;129:832–837.PubMedGoogle Scholar
  12. 12.
    Figadere B, Norman AW, Henry HL, et al. Arocalciferols: synthesis and biological evaluation of aromatic side-chain analogues of 1α,25-Dihydroxyvitamin D3(1α). J Med Chem 1991;34:2452–2463.PubMedGoogle Scholar
  13. 13.
    Zhu G-D CY, Zhou X, Vanderwalle M, et al. Synthesis of C,D-ring modified 1,25-dihydroxyvitamin D analogues: C-ring analogues. Bioorg Med Chem Lett 1996;6:1703–1708.Google Scholar
  14. 14.
    Mehta RR, Bratescu L, Graves JM, et al. Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1 α-hydroxyvitamin D5. Int J Oncol 2000;16:65–73.PubMedGoogle Scholar
  15. 15.
    Paaren HE, Mellon WS, Schnoes HK, DeLuca HF. Ring Astereoisomers of 1-hydroxyvitamin D3 and their relative binding affinities for the intestinal la, 25-dihydroxyvitamin D3 receptor protein. Bioorg Chem 1985;13:62–75.Google Scholar
  16. 16.
    Muralidharan KR, De Lera AR, Isaeff SD, et al. Studies on the A-ring diastereomers of 1α,25-dihydroxyvitamin D3. J Org Chem 1993;58:1895–1899.Google Scholar
  17. 17.
    Reddy S. Synthesis and activity of 3-epi-vitamin D3 compounds for use in treatment of disorders involving aberrant activity of hyperproliferative skin, parathyroid, and bone cells. PCT Int. Patent Appl. WO 98 51,663. Chem Abstr 1999;130:25,229X.Google Scholar
  18. 18.
    Perlman KL SR, Schnoes HK, DeLuca HF. 1-α,25-Dihydroxy-19-nor-vitamin D3, a novel vitamin D-related compound with potential therapeutic activity. Tetrahedron Lett 1990;31:1823–1824.Google Scholar
  19. 19.
    Kanzler S HS, Van de Velde JP, Reischl W. A novel class of vitamin D analogs: synthesis and preliminary biological evaluation. Bioorg Med Chem Lett 1996;6:1865–1868.Google Scholar
  20. 20.
    Posner G, Dai H. 1-(Hydroxyalkyl)-25-hydroxyvitamin D3 analogs of calcitrio1.1. Synthesis. Bioorg Med Chem Lett 1993;3:1829–1834.Google Scholar
  21. 21.
    Posner GH, Lee JK, White MC, et al. Antiproliferative hybrid analogs of the hormone 1α,25-dihydroxyvitamin D(3): design, synthesis, and preliminary biological evaluation. J Org Chem 1997;62:3299–3314.PubMedGoogle Scholar
  22. 22.
    Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 2001;41:421–442.PubMedGoogle Scholar
  23. 23.
    Kelloff GJ, Johnson JR, Crowell JA, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomark Prey 1995;4:1–10.Google Scholar
  24. 24.
    Wali RK, Bissonnette M, Khare S, et al. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1α,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res 1995;55:3050–3054.PubMedGoogle Scholar
  25. 25.
    Colston KW, Mork HC, Hansen C. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002;9:45–59.PubMedGoogle Scholar
  26. 26.
    Quack M, Mork HC, Binderup E, et al. Metabolism of the vitamin D3 analog EB 1089 alters receptor complex formation and reduces promoter selectivity. Br J Pharmacol 1998;125:607–614.PubMedGoogle Scholar
  27. 27.
    Yang W, Freedman LP. 20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor. J Biol Chem 1999;274:16,838–16,845.Google Scholar
  28. 28.
    Li XY, Boudjelal M, Xiao JH, et al. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrinol 1999;13:1686–1694.PubMedGoogle Scholar
  29. 29.
    Peleg S, Nguyen C, Woodard BT, et al. Differential use of transcription activation function 2 domain of the vitamin D receptor by 1,25-dihydroxyvitamin D3 and its A ring-modified analogs. Mol Endocrinol 1998;12:525–535.PubMedGoogle Scholar
  30. 30.
    Fioravanti L, Miodini P, Cappelletti V, DiFronzo G. Synthetic analogs of vitamin D3 have inhibitory effects on breast cancer cell lines. Anticancer Res 1998;18:1703–1708.PubMedGoogle Scholar
  31. 31.
    Pettersson F, Colston KW, Dalgleish AG. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogs on pancreatic cancer cells in vitro. Br J Cancer 2000;83:239–245.PubMedGoogle Scholar
  32. 32.
    Blutt SE, Polek TC, Stewart LV, et al. A calcitriol analogue, EB 1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60:779–782.PubMedGoogle Scholar
  33. 33.
    Liu M, Lee MH, Cohen M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dey 1996;10:142–153.Google Scholar
  34. 34.
    Campbell MJ, Elstner E, Holden S, et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21 waf 1 p27kiP 1 and E-cadherin. J Mol Endocrinol 1997;19:15–27.PubMedGoogle Scholar
  35. 35.
    Rots NY, Liu M, Anderson EC, Freedman LP. A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol Cell Biol 1998;18:1911–1918.PubMedGoogle Scholar
  36. 36.
    Jensen SS, Madsen MW, Lukas J, et al. Inhibitory effects of 1α,25-dihydroxyvitamin D3 on the G1-S phase-controlling machinery. Mol Endocrinol 2001;15:1370–1380.PubMedGoogle Scholar
  37. 37.
    Prudencio J, Akutsu N, Benlimame N, et al. Action of low calcemic 1α,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. J Nall Cancer Inst 2001;93:745–753.Google Scholar
  38. 38.
    Wang QM, Chen F, Luo X, et al. Lowering of p27kiPl levels by its antisense or by development of resistance to 1,25-dihydroxyvitamin D3 reverses the G1 block but not differentiation of HL60 cells. Leukemia 1998;12:1256–1265.PubMedGoogle Scholar
  39. 39.
    Segaert S, Garmyn M, Degreef H, Bouillon R. Retinoic acid modulates the antiproliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes. J Investig Dermatol 1997;109:46–54.PubMedGoogle Scholar
  40. 40.
    Swami S, Krishnan AV, Feldman D. 1α,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 2000;6:3371–3379.PubMedGoogle Scholar
  41. 41.
    Nickerson T, Huynh H. Vitamin D analog EB1089-induced prostate regression is associated with increased gene expres-sion of insulin-like growth factor binding proteins. J Endocrinol 1999;160:223–229.PubMedGoogle Scholar
  42. 42.
    Sundaram S, Chaudhry M, Reardon D, et al. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 2000;63:1–10.PubMedGoogle Scholar
  43. 43.
    Sundaram S, Gewirtz DA. The vitamin D3 analog EB1089 enhances the response of human breast tumor cells to radiation. Radiat Res 1999; 152:479–486.PubMedGoogle Scholar
  44. 44.
    Pirianov G, Colston KW. Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells. Steroids 2001;66:309–318.PubMedGoogle Scholar
  45. 45.
    Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bc1–2 but does not involve known caspases or p53. Cancer Res 1999;59:4848–4856.PubMedGoogle Scholar
  46. 46.
    Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB 1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000;60:2304–2312.PubMedGoogle Scholar
  47. 47.
    Koren R, Hadari-Naor I, Zuck E, et al. Vitamin D is a prooxidant in breast cancer cells. Cancer Res 2001;61:1439–1444.PubMedGoogle Scholar
  48. 48.
    Narvaez CJ, Zinser G, Welsh J. Functions of 1α,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 2001;66:301–308.PubMedGoogle Scholar
  49. 49.
    Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001;276:9101–9107.PubMedGoogle Scholar
  50. 50.
    McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001;276:26,365–26,373.Google Scholar
  51. 51.
    Majewski S, Skopinska M, Marczak M, et al. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1996;1:97–101.PubMedGoogle Scholar
  52. 52.
    Mantell DJ, Owens PE, Bundred NJ, et al. 1α,25-Dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87:214–220.PubMedGoogle Scholar
  53. 53.
    Hara K, Kusuzaki K, Takeshita H, et al. Oral administration of 1 α hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res 2001;21:321–324.PubMedGoogle Scholar
  54. 54.
    Shokravi MT, Marcus DM, Alroy J, et al. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Investig Ophthalmol Vis Sci 1995; 36:83–87.Google Scholar
  55. 55.
    Lokeshwar BL, Schwartz GG, Selzer MG, et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB 1089. Cancer Epidemiol Biomark Prey 1999;8:241–248.Google Scholar
  56. 56.
    Schwartz GG, Wang MH, Zang M, et al. 1α,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prey 1997;6:727–732.Google Scholar
  57. 57.
    Yudoh K, Matsuno H, Kimura T. 1α,25-Dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med 1999;133:120–128.PubMedGoogle Scholar
  58. 58.
    Apperly F. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941;1:191–195.Google Scholar
  59. 59.
    Peller S, Stephenson C. Skin irritation and cancer in the United States Navy. Am J Med Sci 1937;194:326–333.Google Scholar
  60. 60.
    Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227–231.PubMedGoogle Scholar
  61. 61.
    Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prey Med 1990;19:614–622.Google Scholar
  62. 62.
    Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990;19:820–824.PubMedGoogle Scholar
  63. 63.
    Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861–2869.PubMedGoogle Scholar
  64. 64.
    Emerson JC, Weiss NS. Colorectal cancer and solar radiation. Cancer Causes Control 1992;3:95–99.PubMedGoogle Scholar
  65. 65.
    Garland CF, Garland FC, Gorham ED. Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. Ann NY Acad Sci 1999;889:107–119.PubMedGoogle Scholar
  66. 66.
    Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10:1307–1311.PubMedGoogle Scholar
  67. 67.
    Martinez ME, Willett WC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomark Prey 1998;7:163–168.Google Scholar
  68. 68.
    Garland C, Shekelle RB, Barrett-Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985;1:307–309.PubMedGoogle Scholar
  69. 69.
    Bostick RM, Potter JD, Sellers TA, et al. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women’s Health Study. Am J Epidemiol 1993;137:1302–1317.PubMedGoogle Scholar
  70. 70.
    Kearney J, Giovannucci E, Rimm EB, et al. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol 1996;143:907–917.PubMedGoogle Scholar
  71. 71.
    Zheng W, Anderson KE, Kushi LH, et al. A prospective cohort study of intake of calcium, vitamin D, and other micronutrients in relation to incidence of rectal cancer among postmenopausal women. Cancer Epidemiol Biomark Prey 1998;7:221–225.Google Scholar
  72. 72.
    Martinez ME, Giovannucci EL, Colditz GA, et al. Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst 1996;88:1375–1382.PubMedGoogle Scholar
  73. 73.
    Pritchard RS, Baron JA, de Verdier MG. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomark Prey 1996;5:897–900.Google Scholar
  74. 74.
    Marcus PM, Newcomb PA. The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 1998;27:788–793.PubMedGoogle Scholar
  75. 75.
    Boutron MC, Faivre J, Marteau P, et al. Calcium, phosphorus, vitamin D, dairy products and colorectal carcinogenesis: a French case-control study. Br J Cancer 1996;74:145–151.PubMedGoogle Scholar
  76. 76.
    Platz EA, Hankinson SE, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomark Prey 2000;9:1059–1065.Google Scholar
  77. 77.
    Peters U, McGlynn KA, Chatterjee N, et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorec-tal adenomas. Cancer Epidemiol Biomark Prey 2001;10:1267–1274.Google Scholar
  78. 78.
    Holt PR, Arber N, Halmos B, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomark Prey 2002;11:113–119.Google Scholar
  79. 79.
    John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomark Prey 1999;8:399–406.Google Scholar
  80. 80.
    Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomark Prey 1993;2:467–472.Google Scholar
  81. 81.
    Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995;6:235–239.PubMedGoogle Scholar
  82. 82.
    Nomura AM, Stemmermann GN, Lee J, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425–432.PubMedGoogle Scholar
  83. 83.
    Gann PH, Ma J, Hennekens CH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomark Prey 1996;5:121–126.Google Scholar
  84. 84.
    Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomark Prey 1998;7:385–390.Google Scholar
  85. 85.
    Ingles SA, Coetzee GA, Ross RK, et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998;58:1620–1623.PubMedGoogle Scholar
  86. 86.
    Taylor JA, Hirvonen A, Watson M, et al. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108–4110.PubMedGoogle Scholar
  87. 87.
    Hamasaki T, Inatomi H, Katoh T, et al. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J 2001;48:543–549.PubMedGoogle Scholar
  88. 88.
    Gsur A, Madersbacher S, Haidinger G, et al. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002;51:30–34.PubMedGoogle Scholar
  89. 89.
    Bretherton-Watt D, Given-Wilson R, Mansi JL, et al. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 2001;85:171–175.PubMedGoogle Scholar
  90. 90.
    Ingles SA, Garcia DG, Wang W, et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000;11:25–30.PubMedGoogle Scholar
  91. 91.
    Hutchinson PE, Osborne JE, Lear JT, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000;6:498–504.PubMedGoogle Scholar
  92. 92.
    Ingles SA, Wang J, Coetzee GA, et al. Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control 2001;12:607–614.PubMedGoogle Scholar
  93. 93.
    Kim HS, Newcomb PA, Ulrich CM, et al. Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomark Prey 2001;10:869–874.Google Scholar
  94. 94.
    Slatter ML, Yakumo K, Hoffman M, Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 2001;12:359–364.PubMedGoogle Scholar
  95. 95.
    Kawaura A, Tanida N, Nishikawa M, et al. Inhibitory effect of 1α-hydroxyvitamin D3 on N-methyl-N’ -nitro-N-nitrosoguanidine-induced gastrointestinal carcinogenesis in Wistar rats. Cancer Lett 1998;122:227–230.PubMedGoogle Scholar
  96. 96.
    Kawaura A, Tanida N, Sawada K, et al. Supplemental administration of la-hydroxyvitamin D3 inhibits promotion by intrarectal instillation of lithocholic acid in N-methyl-N-nitrosourea-induced colonic tumorigenesis in rats. Carcinogenesis 1989;10:647–649.PubMedGoogle Scholar
  97. 97.
    Iseki K, Tatsuta M, Uehara H, et al. Inhibition of angiogenesis as a mechanism for inhibition by 1α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999;81:730–733.PubMedGoogle Scholar
  98. 98.
    Belleli A, Shany S, Levy J, et al. A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis 1992;13:2293–2298.PubMedGoogle Scholar
  99. 99.
    Evans SR, Shchepotin EI, Young H, et al. 1,25-Dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. Int J Oncol 2000;16:1249–1254.PubMedGoogle Scholar
  100. 100.
    Pence BC, Buddingh F. Inhibition of dietary fat-promoted colon carcinogenesis in rats by supplemental calcium or vitamin D3. Carcinogenesis 1988;9:187–190.PubMedGoogle Scholar
  101. 101.
    Albert DM, Marcus DM, Gallo JP, O’Brien JM. The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Investig Ophthalmol Vis Sci 1992;33:2354–2364.Google Scholar
  102. 102.
    Rubin D, Levij IS. Suppression by vitamins D2 and D3 of hamster cheek pouch carcinoma induced with 9,10-dimethyl-1,2-benzanthracene with a discussion of the role of intracellular calcium in the development of tumors. Pathol Microbiol (Basel) 1973;39:446–460.Google Scholar
  103. 103.
    Wood AW, Chang RL, Huang MT, et al. 1α, 25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 1983;116:605–611.PubMedGoogle Scholar
  104. 104.
    Chida K, Hashiba H, Fukushima M, et al. Inhibition of tumor promotion in mouse skin by 1α,25-dihydroxyvitamin D3. Cancer Res 1985;45:5426–5430.PubMedGoogle Scholar
  105. 105.
    Pence BC, Richard BC, Lawlis RS, Kuratko CN. Effects of dietary calcium and vitamin D3 on tumor promotion in mouse skin. Nutr Cancer 1991;16:171–181.PubMedGoogle Scholar
  106. 106.
    Saez S, Falette N, Guillot C, et al. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res Treat. 1993;27:69–81.PubMedGoogle Scholar
  107. 107.
    Huerta S, Irwin RW, Heber D, et al. 1α,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) Mouse. Cancer Res 2002;62:741–746.PubMedGoogle Scholar
  108. 108.
    Taniyama T, Wanibuchi H, Salim EI, et al. Chemopreventive effect of 24R,25-dihydroxyvitamin D(3) in N, N’-dimethyl-hydrazine-induced rat colon carcinogenesis. Carcinogenesis 2000;21:173–178.PubMedGoogle Scholar
  109. 109.
    Otoshi T, Iwata H, Kitano M, et al. Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxacalcitriol, a synthetic analogue of la, 25-dihydroxyvitamin D3. Carcinogenesis 1995;16:2091–2097.PubMedGoogle Scholar
  110. 110.
    Brown AJ, Slatopolsky E. Vitamin D analogs: perspectives for treatment. Miner Electrolyte Metab 1999;25:337–341.PubMedGoogle Scholar
  111. 111.
    Oikawa T, Yoshida Y, Shimamura M, et al. Antitumor effect of 22-oxa-1 α,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 1991;2:475–480.PubMedGoogle Scholar
  112. 112.
    Mehta RG, Moriarty RM, Mehta RR, et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1 α-hydroxyvitamin D5. J Natl Cancer Inst 1997;89:212–218.PubMedGoogle Scholar
  113. 113.
    Mehta R, Hawthorne M, Uselding L, et al. Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1 α-hydroxyvitamin D(5). J Natl Cancer Inst 2000;92:1836–1840.PubMedGoogle Scholar
  114. 114.
    Anzano MA, Smith JM, Uskokovic MR, et al. lα,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24–5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54:1653–1656.PubMedGoogle Scholar
  115. 115.
    Ikezaki S, Nishikawa A, Furukawa F, et al. Chemopreventive effects of 24R,25-dihydroxyvitamin D3, a vitamin D3 derivative, on glandular stomach carcinogenesis induced in rats by N-methyl-N’-nitro-N-nitrosoguanidine and sodium chloride. Cancer Res 1996;56:2767–2770.PubMedGoogle Scholar
  116. 116.
    Lucia MS, Anzano MA, Slayter MV, et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analog Ro24–5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 1995;55:5621–5627.PubMedGoogle Scholar
  117. 117.
    Sporn MB. New agents for chemoprevention of prostate cancer. Eur Urol 1999;35:420–423.PubMedGoogle Scholar
  118. 118.
    Kensler TW, Dolan PM, Gange SJ, et al. Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. Carcinogenesis 2000;21:1341–1345.PubMedGoogle Scholar
  119. 119.
    Norman AW. The vitamin D endocrine system: manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. J Cell Biochem Suppl 1995;22:218–225.PubMedGoogle Scholar
  120. 120.
    Konety BR, Johnson CS, Trump DL, Getzenberg RH. Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol 1999;17:77–84.PubMedGoogle Scholar
  121. 121.
    Miller GJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev 1998;17:353–360.PubMedGoogle Scholar
  122. 122.
    Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 1992;13:765–784.PubMedGoogle Scholar
  123. 123.
    Pakkala S, de Vos S, Elstner E, et al. Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leuk Res 1995;19:65–72.PubMedGoogle Scholar
  124. 124.
    Smith EA, Frankenburg EP, Goldstein SA, et al. Effects of long-term administration of vitamin D3 analogs to mice. J Endocrinol 2000;165:163–172.PubMedGoogle Scholar
  125. 125.
    Posner GH, Lee JK, Wang Q, et al. Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogs of the hormone 1α, 25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. J Med Chem 1998;41:3008–3014.PubMedGoogle Scholar
  126. 126.
    Koshizuka K, Koike M, Asou H, et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 1999;53:113–120.PubMedGoogle Scholar
  127. 127.
    Frazao JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1 α-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000;36:550–561.PubMedGoogle Scholar
  128. 128.
    Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1α-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532–543.PubMedGoogle Scholar
  129. 129.
    Sjoden G, Smith C, Lindgren U, DeLuca HF. 1α-Hydroxyvitamin D2 is less toxic than 1α-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985;178:432–436.PubMedGoogle Scholar
  130. 130.
    Weber K, Goldberg M, Stangassinger M, Erben RG. 1α-Hydroxyvitamin D2 is less toxic but not bone selective relative to 1α-hydroxyvitamin D3 in ovariectomized rats. J Bone Mineral Res 2001;16:639–651.Google Scholar
  131. 131.
    Bailey HH, Ripple G., Horvath, D, et al. Phase I and II trials of 1-hydroxyvitamin D2 in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2000;6:4488s, abst no 112.Google Scholar
  132. 132.
    Hansen CM, Hamberg KJ, Binderup E, Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 2000;6:803–828.PubMedGoogle Scholar
  133. 133.
    Gulliford T, English J, Colston KW, et al. A Phase I study of the vitamin D analogue EB1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998;78:6–13.PubMedGoogle Scholar
  134. 134.
    Evans TR, Colston KW, Lofts FJ, et al. A Phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86:680–685.PubMedGoogle Scholar
  135. 135.
    Hsu JY, Feldman D, McNeal JE, Peehl DM. Reduced 1α-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001;61:2852–2856.PubMedGoogle Scholar
  136. 136.
    Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-Hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 2001;357:1673–1674.PubMedGoogle Scholar
  137. 137.
    Koga M, Sutherland RL. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T 47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol 1991;39:455–460.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Kathryn Z. Guyton
  • Thomas W. Kensler
  • Gary H. Posner

There are no affiliations available

Personalised recommendations